about
Current Status of Nuclear Medicine Practice in the Middle EastCharacterization of a novel prokaryotic GDP dissociation inhibitor domain from the G protein coupled membrane protein FeoBEvaluation and comparison of human absorbed dose of (90)Y-DOTA-Cetuximab in various age groups based on distribution data in rats.Preliminary dosimetric evaluation of (166)Ho-TTHMP for human based on biodistribution data in rats.Assessment of human effective absorbed dose of 67 Ga-ECC based on biodistribution rat data.Estimated human absorbed dose for (68)Ga-ECC based on mice data: comparison with (67)Ga-ECC.Development of (153) Sm-folate-polyethyleneimine-conjugated chitosan nanoparticles for targeted therapy.Comparison of estimated human dose of (68)Ga-MAA with (99m)Tc-MAA based on rat data.Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in ratsPreliminary dosimetry of (166)Ho-propylene di-amino tetra (methy1enephosphonicacid) for human based on biodistribution data in rats.Determination of human absorbed dose of 67GA-DTPA-ACTH based on distribution data in rats.Determination of human absorbed dose of 201Tl(III)-DTPA-HIgG based on biodistribution data in rats.Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data.Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation AgentAssessment of effective absorbed dose of (111)In-DTPA-Buserelin in human on the basis of biodistribution rat data.Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphomaApplication of radioisotopes in inflammation.Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis.Synthesis and Evaluation of [(67)Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4.Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran.Development of a (68)Ga-peptide tracer for PET GnRH1-imaging.Development of [⁶⁴Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging.Grafting of [(64)Cu]-TPPF20 porphyrin complex on Functionalized nano-porous MCM-41 silica as a potential cancer imaging agent.Preclinical evaluation of [¹¹¹ In]-DOTA-trastuzumab for clinical trials.Development of a radiolabeled amlodipine analog for L-type calcium channel imaging.Direct Technetium radiopharmaceuticals production using a 30MeV Cyclotron.Preclinical Study of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human OrgansMetastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid.Preparation and preclinical evaluation of 68Ga-DOTA-amlodipine for L-type calcium channel imagingComparison of immune responses against FMD by a DNA vaccine encoding the FMDV/O/IRN/2007 VP1 gene and the conventional inactivated vaccine in an animal model.Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.Development of ga-67 maltolate complex as an imaging agent.Preparation and Biological Study of (68)Ga-DOTA-alendronate.Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation.Grafting of a novel gold(III) complex on nanoporous MCM-41 and evaluation of its toxicity in Saccharomyces cerevisiae.Development of a (68)Ga-Fluorinated Porphyrin Complex as a Possible PET Imaging Agent.Development of (166)Ho-phytate Complex for Radiosynovectomy.Preparation and Evaluation of (68)Ga-ECC as a PET Renal Imaging Agent.Modeling the time dependent biodistribution of Samarium-153 ethylenediamine tetramethylene phosphonate using compartmental analysis.
P50
Q26745479-3B06C716-4496-4ADC-AF22-27EE1A725548Q28755380-7D819173-1165-4E18-98D0-2ABF595527DCQ30584781-E9A922FB-5DE7-459D-84BE-F18DD5E7EBBEQ30855154-8446DECF-F7B4-4EBF-90D9-6974E2863734Q30860016-504A32E7-DAF8-477E-B200-EEFDFFC9C377Q30919395-BBB7ABA1-7E90-4951-9011-C41FDFC35A3FQ30963856-98DE8247-931B-4490-8A16-933016924EC7Q30978368-7D0D4A37-3B85-41A7-944D-2B397522A0B3Q30980121-DB93A149-F3C1-402D-97B8-31D78E8EB527Q31046277-3FA3CCCB-5077-422C-AADE-1B3349B1EF00Q33453036-56CC3E01-42D4-46C0-96CE-2A4F4729EB0AQ33606624-4434ABB2-2BAA-4839-9CEF-73857A4D751BQ33743818-65F84AC0-834C-4B79-9A32-824B0D7B9D25Q34111220-1BC07074-0A1C-4757-A2BC-731D52462DD2Q34371904-E51EEA87-EC5D-419D-BE36-2F633B2B3C97Q34669139-5B9C9128-CC64-478A-A5EB-D2FA7B2E5901Q36447212-EAFE855C-453F-44F9-B73D-1B2224C62653Q37077241-1E88AF2B-3E20-41CF-A166-D2A759007293Q37632872-D616FB2E-1E59-4F98-9CC3-D5BA11EC2A24Q38283709-BFC4CFC7-7BC3-485C-BB1E-39A0CF4C089DQ38380075-189482D1-5A9B-46DB-9BBA-78DBF69EE564Q38777801-47A327DE-72C1-4A09-B9AE-4D7DFA5CC2A3Q38829093-F5C85412-7078-470C-9A40-EA3FDFCA90D6Q38895488-FE4D0A59-AD3B-4FD5-8976-509049BB26CEQ39001450-2FD01EA6-F8DC-4599-A0A8-E07C2F2CC092Q39037949-1CECEA26-F346-4ED2-AB4F-20B2D2F32243Q39118478-87D9BB9F-068C-4CE9-9B87-6324473A717CQ39140677-F49CDBB5-6753-403D-9F40-227CF368110EQ39187541-7869BF01-4192-49DA-9843-B57350501DB7Q39197637-7FF0A54B-C1D4-437A-B845-4E45055188CDQ39273409-6726C798-33F8-4CEA-A2BF-CCA179522352Q39401710-8689455B-C6C0-40DF-BC97-141A1D242517Q39594781-3BA92A97-2FF3-4DA3-81B6-29902F99D6C2Q39607584-F8611346-F2FF-4898-A294-142656C2ECE0Q39607619-A7915469-FE68-46E4-9546-A074EAF78620Q40207558-9508DA72-1DB0-41B9-9668-EBFE3A09052BQ40218691-AEC244E0-1A8E-4E61-B86C-B2A161D3A36AQ40220056-EA49511F-CD15-4D21-884E-4B3842FDA236Q40636739-B7EB980E-5F61-4DD3-AC9C-3D1725D65B19Q40671776-8B2F9CB5-2C0B-4685-819A-9A70A85D3199
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Amir Reza Jalilian
@ast
Amir Reza Jalilian
@en
Amir Reza Jalilian
@es
Amir Reza Jalilian
@nl
type
label
Amir Reza Jalilian
@ast
Amir Reza Jalilian
@en
Amir Reza Jalilian
@es
Amir Reza Jalilian
@nl
altLabel
Amir R Jalilian
@en
prefLabel
Amir Reza Jalilian
@ast
Amir Reza Jalilian
@en
Amir Reza Jalilian
@es
Amir Reza Jalilian
@nl
P106
P21
P213
0000 0004 2253 8610
P214
61145066481566591449
P31
P496
0000-0002-1948-0580
P7859
viaf-61145066481566591449